June 18, 2020
Beginning in June, SNMMI and our Appropriate Payment Coalition Partners, the Medical Imaging Technology Alliance (MITA) and the Council on Radionuclides and Radiopharmaceuticals, Inc. (CORAR) renewed their efforts to continue promoting H.R. 3772, the Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019. This act would extend equitable reimbursement for approved PET agents and thereby stimulate development of new diagnostic radiopharmaceuticals. Three radiopharmaceuticals used to diagnose Alzheimer's Disease are scheduled to be bundled on September 30, 2020.
Participants are organized into teams—each including perspectives from industry, providers, and patients—that virtually visited specific congressional offices. In all, the teams aim to participate in more than 50 meetings, educating congressional representatives and staff about the importance of nuclear medicine and molecular imaging. The enormous financial burden COVID-19 has had on hospitals systems was also communicated. Lack revenue-producing elective procedures coupled with the demands of COVID-19, will likely mean hospitals will be reluctant to support innovative nuclear medicine services because of inadequate reimbursement.
With the end of the current legislative session fast approaching, we need your help!